EU MDR 2017/745 for Dental Devices: Complete Guide (2026)

Dental device regulation under EU MDR 2017/745 has increased the level of scrutiny applied to manufacturers, particularly in three areas: classification decisions, clinical evidence, and Notified Body (NB) review readiness. The practical consequence is simple: submissions that lack internal consistency generate more questions, longer review cycles, and avoidable delays.

In the 2026 webinar delivered by regulatory experts from MDx CRO, the discussion focused on the most common challenges and the most reliable strategies for dental device manufacturers. The insights were grounded in real-world regulatory work supporting more than 500 CE-marked devices, with an emphasis on reducing regulatory risk and building submissions that remain defensible under NB assessment.

Manufacturer priorities under EU MDR: what drives timelines and outcomes

EU MDR does not typically create delays because manufacturers do not have documents. Delays occur when documentation does not form a single, defensible position. Notified Bodies escalate questions when claims, classification rationale, risk controls, clinical evidence, and post-market plans do not support the same intended purpose and performance narrative.

Key priorities for dental device manufacturers under EU MDR:

• Establish and maintain a consistent intended purpose and claim set across the file (labeling, IFU, CER, and technical documentation).
• Build a classification rationale that is explicit, referenced, and difficult to misinterpret.
• Demonstrate clinical evidence proportionality, clearly linked to risk, novelty, and claims.
• Prepare for NB review with a coherent evidence package, including traceability from hazards to controls to verification.
• Ensure PMS and PMCF are designed to confirm performance and safety in real use, not to satisfy a formal requirement.

A submission is reviewed as an argument supported by evidence. When the argument changes between sections of the file, the NB must resolve the conflict through questions. That process is where time is lost.

Step 1. Classify your dental device correctly (Annex VIII)

Classification under Annex VIII is the point where regulatory strategy becomes operational. A small change in intended purpose or in device characteristics can shift the class and materially change clinical evidence expectations, NB involvement, and post-market obligations.

In the webinar, the discussion repeatedly returned to the importance of early discipline around intended purpose. Dental manufacturers often broaden claims for commercial reasons (for example, broad “compatibility” claims or biologically ambitious performance language). Under MDR, that approach frequently increases the burden of proof.

Practical classification anchors in dental:

• Implants and implantable devices frequently fall under Rule 8, with class outcomes dependent on specific characteristics and risk context.
• Resorbable materials often face elevated scrutiny because performance and safety evolve as the product degrades and interacts with tissue.
• Custom-made versus patient-matched frequently causes misclassification and incorrect pathway selection, particularly in digital workflows.
• Software classification under Rule 11 can change significantly based on clinical impact and decision influence.

A defensible classification process typically answers these questions explicitly:

• What is the intended purpose and what claims are being made?
• Is the device invasive, and if so, what level of invasiveness applies?
• What is the duration of use and the relevant contact type?
• Is the device implantable, resorbable, or otherwise associated with long-term biological interaction?
• Does the device incorporate a medicinal substance with an ancillary action?
• Is any element of the product regulated as software influencing clinical decisions?

Classification is assessed as a justification, not a label. A strong justification reduces NB discretion and stabilises the remainder of the submission.

Step 2. Conformity assessment route by class, and how Notified Bodies evaluate risk

Manufacturers often plan around the conformity assessment route, but Notified Bodies allocate effort based on what drives residual risk and uncertainty. Under MDR, two devices of the same class can attract different levels of scrutiny when novelty, claim strength, or evidence quality differs.

In dental, common drivers of NB scrutiny include:

• Novel materials and surface treatments particularly where particulate generation, chemical residues, coating stability, or long-term performance need stronger justification.
• Compatibility and system claims, especially for implant components and abutments, where broad claims are difficult to support without precise system definition and evidence.
• Borderline product categorisation, such as semi-finished CAD/CAM materials, where intended purpose determines medical device status.
• Digital workflows, where the manufacturer controls design parameters and outputs are patient-specific within defined constraints.

From a submission strategy perspective, the objective is to reduce uncertainty for the reviewer. That is achieved by ensuring the file communicates a consistent position:

• The intended purpose and claims are consistent and reflected in labeling and IFU.
• The classification rationale is explicit and mapped to Annex VIII logic.
• Risk controls are linked to verification and validation evidence.
• Clinical evaluation is proportionate and aligned to claims.
• PMS and PMCF demonstrate control over real-world performance.

The NB review process accelerates when the documentation structure allows rapid verification of consistency. It slows down when the reviewer has to reconcile contradictions between sections.

Step 3. Clinical evidence strategy for dental devices: CER, PMCF, and clinical investigations.

Clinical evidence is typically the largest schedule and cost driver under MDR. The core issue is not volume; it is relevance and alignment to the intended purpose, claims, and risk profile.

A manufacturer-ready clinical evidence strategy generally combines:

• A Clinical Evaluation Report (CER) anchored to intended purpose and claims.
• Literature appraisal aligned with state of the art and device technology.
• Post-market surveillance (PMS) data, including complaint trending and failure mode monitoring.
• A PMCF approach proportionate to risk and uncertainty, designed to confirm performance and safety in clinical use.

The webinar highlighted a recurring decision point for manufacturers: when “well-established technology” is an appropriate foundation for clinical justification, and when novelty requires additional clinical evidence.

Practical examples discussed in dental context:

• Implantables may be approached differently depending on the maturity of the technology, materials, and the presence of novel surface engineering or expanded clinical claims.
• Resorbable grafting materials and membranes often require particular attention to degradation behaviour, degradation by-products, biological response, and performance endpoints over time.
• Legacy devices require a structured assessment of whether existing data remains fit for MDR expectations and current clinical practice.

Notified Bodies evaluate clinical evidence against the totality of the file. Evidence is rarely accepted in isolation if risk management, claims, and verification logic do not support it.

How to pass a Notified Body Assessment as a dental device manufacturer

In practice, manufacturers do not lose time because they miss a single document. They lose time when their file is not reviewable as a system. Notified Bodies move more efficiently when traceability is clear and when the submission reads as one coherent position.

A practical Assessment-readiness checklist:

• Intended purpose and claims are consistent across IFU, labeling, CER, and technical documentation.
• Classification is justified with explicit Annex VIII logic and references.
• Risk management is device-specific and connects hazards to controls and to verification evidence.
• Verification and validation are planned around worst cases, critical characteristics, and real-use conditions.
• Clinical evaluation is aligned to claims and supported by appropriate PMS/PMCF.
• PMS/PMCF plans are measurable, realistic, and proportionate.

The NB-ready evidence pack (manufacturer checklist)

For internal alignment and faster NB interaction, a compact evidence pack is often effective. A practical NB-ready pack includes:

• Device description, intended purpose, and claim list (single source of truth)
• Annex VIII classification memorandum (rule logic and rationale)
• GSPR checklist with clear evidence references
• Risk management file (ISO 14971) and traceability to controls
• Verification and validation plan and reports (including worst-case rationale)
• Biological evaluation strategy (ISO 10993) and, where relevant, extractables and leachables considerations
• Mechanical performance evidence, acceptance criteria, and justification of test conditions
• Clinical evaluation (CER), literature strategy, and equivalence rationale when applicable
• PMS plan and PMCF plan/report (tailored to failure modes and risk profile)
• Labeling and IFU, including UDI readiness and EUDAMED considerations as applicable

The evidence pack is not a marketing summary. It is a reviewer tool. Its value is to reduce time spent locating and reconciling information across the file.

How to categorise dental devices under EU MDR (classification shortcuts by product type)

Dental manufacturers rarely struggle with the existence of Annex VIII. The difficulty is applying it consistently across a portfolio that mixes implantables, materials, digital workflows, and patient-specific outputs. A practical way to reduce ambiguity is to group dental devices by product type first, then confirm the applicable MDR rules and evidence expectations.

• Dental implants and abutments
  Typical focus areas include the Annex VIII rationale (often centred on implantability), the scope of compatibility claims (system-specific definition), mechanical performance evidence, and the regulatory impact of surface treatments and coatings.
• Resorbable grafting materials, membranes, and hemostats
  These products often require careful justification of degradation behaviour, degradation by-products, biological response over time, and clinically relevant endpoints. Evidence expectations frequently increase with resorption and biological interaction.
• Restoratives and CAD/CAM materials (including semi-finished products)
  Categorisation often depends on intended purpose and how the manufacturer positions the product (medical device versus material). Performance claims, manufacturing controls, and labeling language typically drive both classification stability and clinical evidence requirements.
• Custom-made versus patient-matched devices
  The practical distinction is design control. Custom-made devices require a prescription-led pathway with specific documentation, while patient-matched outputs often operate within a validated design envelope controlled by the manufacturer. This distinction materially affects technical documentation and lifecycle obligations.
• Dental software, AI, and digital workflows
  Software categorisation under Rule 11 depends on how the software influences clinical decisions and outcomes. Validation, cybersecurity, and change control become central, and AI governance requirements can intersect with technical documentation expectations.

Common dental device categories to review:

A structured categorisation approach helps manufacturers align intended purpose, classification rationale, verification planning, and clinical evidence strategy across the full file, which reduces clarification cycles during review.

To learn more about dental device regulation and compliance support, read: Regulatory Compliance for Dental Products.

PMS, PMCF, UDI/EUDAMED, and legacy devices: maintaining market access

Under MDR, post-market obligations are part of the evidence lifecycle. PMS and PMCF support the ongoing demonstration of safety and performance and can become decisive during renewals and significant changes.

Practical PMS and PMCF considerations in dental:

• Define and monitor meaningful signals: failures, revisions, fractures, loosening, complaint patterns, and trends linked to known failure modes.
• Ensure PMCF is proportionate and focused on remaining uncertainty, rather than generic data collection.
• Maintain a controlled approach to labeling updates, complaint handling, and vigilance reporting.

For legacy devices, manufacturers should perform a structured assessment of whether existing clinical and post-market data remains sufficient for current claims, current clinical practice, and MDR expectations. Where gaps exist, a targeted plan that links risk management to clinical evaluation and post-market follow-up reduces uncertainty and supports continuity of market access.

MDR transition in practice: Argen dental alloys case study

Many MDR transitions fail for predictable reasons: legacy documentation does not meet MDR expectations, clinical evaluation lacks alignment to intended purpose and risk management, and post-market systems are not mature enough to support lifecycle obligations. A recent example from dental materials demonstrates what a structured transition can look like in practice.

Argen transitioned a legacy dental alloy portfolio to Regulation (EU) 2017/745 for use in fabricating full-cast and ceramic-veneered restorations (including crowns, bridges, and removable partial dentures). The project required closing historical Notified Body non-conformities and strengthening core regulatory processes to achieve an audit-ready MDR position

What the work focused on:

• Strengthening the clinical evaluation framework
• Structuring the PMS system
• Aligning risk management with MDR and ISO 14971
• Establishing MDR-compliant biological evaluation
• Aligning essential technical documentation

To read the full case study, click here: Case Study: How MDx Enabled Argen’s Successful Transition to MDR CE Marking for Dental Alloys.

Frequently Asked Questions About Dental Device Regulation